Ovulation induction (OI) is a fertility treatment that uses medication to stimulate the ovaries to produce and release eggs.
It is often combined with timed intercourse or assisted procedures such as intra-uterine insemination (IUI) to increase the chances of conception during the most fertile window.
Ovulation induction (OI) helps improve the chances of pregnancy by ensuring that ovulation occurs at the right time and that one or more eggs are released.
This allows couples to time intercourse or fertility procedures more effectively during the fertile period.
Ovulation induction (OI) may be recommended for women who experience:
It is also used when ovulation support is needed before IVF or IUI.
Ovulation induction (OI) is commonly recommended when ovulation does not occur regularly, when natural conception has not been successful, or when a less invasive fertility treatment is preferred before progressing to IVF.
Ovulation induction (OI) is preceded by a full fertility assessment.
This may include hormonal blood tests, ovarian reserve evaluation, pelvic ultrasound for women, and semen analysis for men to ensure treatment is safe and appropriate.
Ovulation induction (OI) commonly uses two medications:
The choice depends on diagnosis, age, and previous treatment response, as determined by our fertility specialist.
Ovulation induction (OI) using Clomiphene works by stimulating the brain to increase follicle-stimulating hormone (FSH), which encourages the ovaries to develop and release eggs.
It is often used in irregular ovulation or early fertility treatment.
Ovulation induction (OI) with Letrozole involves temporarily lowering oestrogen levels to stimulate natural hormonal signals that trigger ovulation.
It is particularly effective for women with polycystic ovary syndrome (PCOS).
Ovulation induction (OI) using Letrozole is often effective for women with PCOS because it helps regulate ovulation.
It supports more predictable egg release in cases where natural ovulation is irregular or absent.
Ovulation induction (OI) is often combined with timed intercourse, where couples are advised to have sexual intercourse during the most fertile days around ovulation to maximise the chance of conception.
Ovulation induction (OI) is monitored using ultrasound scans to track follicle growth and sometimes blood tests to assess hormonal response.
This ensures accurate timing for ovulation and conception.
Ovulation induction (OI) itself is not painful as it involves oral medication and routine monitoring.
Some women may experience mild side effects such as bloating, headaches, or mood changes depending on the medication used.
Ovulation induction (OI) success rates vary depending on age, underlying fertility conditions, and reproductive health.
It is generally more effective when closely monitored and combined with timed intercourse or IUI.
Ovulation induction (OI) is generally safe when supervised by fertility specialists.
Regular monitoring through scans and hormonal tests ensures a controlled and safe response to medication.
Ovulation induction (OI) is often used before IVF as a first-line treatment for ovulation-related fertility issues.
It is less invasive and may be effective for some couples before progressing to advanced treatments.
Ovulation induction (OI) requires a fertility assessment to ensure the treatment is suitable.
This helps identify underlying conditions and allows for a personalised treatment plan that improves effectiveness and safety.
Most of our patients experience only mild discomfort.
The procedure is quick, simple, and minimally invasive.
Yes. Ovulation induction (OI) medications can improve the chances of success, and we personalise the treatment for each patient.
Pregnancy testing is usually done 2 weeks after intra-uterine insemination (IUI) to ensure the most accurate result.
In-vitro fertilisation (IVF) is an advanced fertility treatment where eggs are retrieved from the ovaries and fertilised with sperm in a laboratory setting.
The resulting embryos are then transferred into the uterus to help achieve pregnancy, particularly when natural conception is difficult.
In-vitro fertilisation (IVF) may benefit individuals or couples experiencing conditions such as endometriosis, blocked fallopian tubes, severe male factor infertility, advanced maternal age, unexplained infertility, or genetic disorders like Thalassaemia.
It may also be recommended when donor eggs or sperms are required.
In-vitro fertilisation (IVF) is usually considered when simpler treatments such as timed intercourse or IUI have not been successful, or when fertility assessment shows significant issues with egg, sperm, or embryo quality. It may also be recommended for genetic screening needs or recurrent miscarriage.
In-vitro fertilisation (IVF) begins with a detailed fertility evaluation for both partners.
This includes medical history review, hormonal testing, ovarian reserve assessment, pelvic ultrasound for women, and semen analysis for men to guide a personalised treatment plan.
In-vitro fertilisation (IVF) uses hormonal medication to stimulate the ovaries to produce multiple eggs.
This process usually starts on day 2 or 3 of the menstrual cycle and lasts around 10 to 12 days, depending on the individual treatment protocol.
In-vitro fertilisation (IVF) includes a procedure called oocyte pick-up (OPU), where eggs are collected from the ovaries using a minimally invasive technique.
It is performed under light anaesthesia or sedation and typically takes about 20 to 30 minutes.
In-vitro fertilisation (IVF) egg retrieval is generally not painful because it is performed under sedation or light anaesthesia.
Most patients experience only mild bloating or cramping afterwards and can return to normal activities the following day.
In-vitro fertilisation (IVF) involves fertilising eggs with sperm in a laboratory using advanced techniques such as conventional fertilisation, intra-cytoplasmic sperm injection (ICSI), physiological intra-cytoplasmic sperm injection (PICSI), or intra-cytoplasmic morphologically selected sperm injection (IMSI), depending on the patient’s fertility condition.
In-vitro fertilisation (IVF) may include intra-cytoplasmic sperm injection (ICSI), a technique where a single sperm is directly injected into an egg to assist fertilisation.
It is commonly used for male factor infertility, low sperm count, or previous fertilisation failure.
In-vitro fertilisation (IVF) may use physiological intra-cytoplasmic sperm injection (PICSI) to select mature and functionally strong sperm by allowing them to bind to hyaluronic acid before injection.
This may improve embryo development in certain cases of male infertility.
In-vitro fertilisation (IVF) may include intra-cytoplasmic morphologically selected sperm injection (IMSI), which uses high-magnification imaging to select sperm with the best morphology before injection into the egg.
It is often used in severe male infertility or repeated IVF failure cases.
In-vitro fertilisation (IVF) embryos are cultured in the laboratory for 5 to 7 days until they reach the blastocyst stage.
During this period, our embryologists monitor their development before selecting the best embryo for transfer.
In-vitro fertilisation (IVF) embryo transfer is the process of placing a selected embryo into the uterus.
Any additional high-quality embryos may be frozen for future use if needed.
In-vitro fertilisation (IVF) typically takes around 4 to 6 weeks from ovarian stimulation to embryo transfer, depending on individual response and treatment protocol.
Some patients may experience mild discomfort during egg retrieval.
However, the overall experience can vary depending on the skill and experience of the fertility specialist performing the procedure.
At Sunfert, all our fertility specialists are highly trained and bring years of experience, helping ensure each procedure is performed with precision, care, and patient comfort in mind.
In-vitro fertilisation (IVF) is a fertility treatment where eggs and sperm are combined in a laboratory dish to allow natural fertilisation.
Intra-Cytoplasmic Sperm Injection (ICSI) is a specialised technique where a single sperm is directly injected into an egg to improve fertilisation chances.
At Sunfert, our embryologists often apply ICSI for patients with:
There will be no extra charges for ICSI at Sunfert International Fertility Centre.
In-vitro fertilisation (IVF) results are usually confirmed through a pregnancy blood test (beta hCG) about 2 weeks after embryo transfer.
This provides an accurate indication of implantation success.
Intra-cytoplasmic sperm injection (ICSI) is an advanced IVF technique where a single healthy sperm is directly injected into a mature egg.
This helps improve fertilisation chances, especially in cases of male infertility or previous fertilisation difficulties.
Intra-cytoplasmic sperm injection (ICSI) differs from conventional IVF because instead of allowing sperm to naturally fertilise the egg in a laboratory dish, a single selected sperm is directly injected into the egg.
This increases the chance of successful fertilisation in certain fertility cases.
Intra-cytoplasmic sperm injection (ICSI) may benefit couples with low sperm count, poor sperm motility, abnormal sperm shape, previous IVF fertilisation failure, ejaculation disorders, or those requiring sperm retrieval procedures such as TESE or PESA.
Intra-cytoplasmic sperm injection (ICSI) is recommended when there are significant male fertility issues, previous failed fertilisation in IVF cycles, or when sperm needs to be retrieved surgically due to medical conditions or reproductive surgery.
Intra-cytoplasmic sperm injection (ICSI) itself is not painful because it is carried out entirely in the laboratory.
The procedure involves handling eggs and sperm outside the body.
Intra-cytoplasmic sperm injection (ICSI) significantly improves fertilisation rates, particularly in male-factor infertility.
However, fertilisation is still influenced by factors such as egg quality, sperm health, and overall reproductive conditions.
In intra-cytoplasmic sperm injection (ICSI), embryologists carefully select a single sperm with the best shape and movement for each egg.
This helps improve the chances of successful fertilisation in a controlled laboratory environment.
An intra-cytoplasmic sperm injection (ICSI) cycle typically takes around 4 to 6 weeks from ovarian stimulation to embryo transfer, depending on individual response and treatment planning.
No. At Sunfert, our embryologists review the clinical need for intra-cytoplasmic sperm injection (ICSI), and if it is required, they will perform it accordingly at no additional charge to our patients.
Intra-cytoplasmic sperm injection (ICSI) is a safe and is widely used in fertility treatment.
However, its success and safety depends on several factors, including:
Intra-cytoplasmic sperm injection (ICSI) can be combined with Pre-implantation Genetic Testing (PGT-A or PGT-M) to screen embryos for chromosomal or genetic conditions before transfer, helping support informed reproductive decisions.
A fertility assessment before intra-cytoplasmic sperm injection (ICSI) helps identify the underlying cause of infertility and ensures the treatment plan is personalised, appropriate, and medically justified for both partners.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) is an advanced form of intra-cytoplasmic sperm injection (ICSI) that uses ultra-high magnification (up to 6,000 to 7,000 times) to select sperm with the best structural quality before injection into the egg.
This allows more detailed assessment of sperm head, nucleus, and vacuoles to improve selection precision.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) differs from standard intra-cytoplasmic sperm injection (ICSI) by using significantly higher magnification to evaluate sperm morphology in greater detail.
This helps our embryologists at Sunfert to select sperm with optimal structural integrity, especially in complex male infertility cases.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) may benefit patients with severe sperm morphology abnormalities, repeated IVF or ICSI failure, poor embryo development, recurrent implantation failure, or selected cases of high sperm DNA fragmentation or advanced paternal age.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) is recommended when previous intra-cytoplasmic sperm injection (ICSI) cycles have failed, embryos fertilise but do not develop well, implantation repeatedly fails, or semen analysis shows significant sperm morphology issues.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) involves examining sperm under ultra-high magnification to assess detailed morphology, including nuclear shape and vacuole presence.
Only sperm with optimal structural integrity are selected for fertilisation.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) itself is not painful for patients.
The procedure is performed in the laboratory.
Egg retrieval and embryo transfer are done under appropriate medical care, with minimal discomfort managed by sedation or clinical support.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) may improve outcomes in selected cases, particularly where sperm morphology is severely abnormal or previous IVF cycles have failed.
However, it is not required for all patients undergoing IVF.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) is not universally better than intra-cytoplasmic sperm injection (ICSI).
It offers enhanced sperm selection precision and is mainly beneficial in specific male infertility cases rather than routine use.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) can be combined with Pre-implantation Genetic Testing (PGT-A or PGT-M) to help screen embryos for chromosomal or genetic disorder before transfer.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) is considered safe and follows the same clinical and laboratory safety standards as intra-cytoplasmic sperm injection (ICSI), with additional precision in sperm selection under high magnification.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) involves a detailed fertility assessment to determine whether advanced sperm selection is clinically appropriate.
This ensures treatment is evidence-based and tailored to each couple’s needs.
At Sunfert, transparency is a core value. We only recommend additional procedures when there is clear clinical evidence that they may benefit our patients.
Intra-cytoplasmic morphologically-selected sperm injection (IMSI) is not widely available at all fertility centres, as it requires significant investment in specialised equipment and highly trained embryologists to perform the procedure.
At Sunfert, as one of the prominent fertility service providers in Malaysia, we offer a full range of fertility services, including IMSI.
Physiological intra-cytoplasmic sperm injection (PICSI) is an advanced sperm selection technique used in IVF that helps our embryologists choose more mature and genetically competent sperm. It works by identifying sperm that can bind to hyaluronic acid, a natural substance surrounding the egg, which indicates better sperm maturity and DNA integrity.
Physiological intra-cytoplasmic sperm injection (PICSI) differs from standard intra-cytoplasmic sperm injection (ICSI) by using a biological selection method rather than visual assessment alone.
Instead of selecting sperm based only on shape and movement, PICSI identifies sperm that naturally bind to hyaluronic acid, which is linked to higher maturity and better DNA quality.
Physiological intra-cytoplasmic sperm injection (PICSI) may benefit couples with repeated implantation failure, previous fertilisation issues, elevated sperm DNA fragmentation, abnormal sperm morphology, or unexplained infertility where sperm quality may be a contributing factor.
Physiological intra-cytoplasmic sperm injection (PICSI) is recommended when previous intra-cytoplasmic sperm injection (ICSI) cycles have not achieved optimal fertilisation, when sperm DNA integrity is a concern, or when male fertility parameters indicate borderline or compromised sperm quality.
In physiological intra-cytoplasmic sperm injection (PICSI), sperm are placed in a hyaluronic acid-coated dish.
Mature sperm bind to the surface naturally, and embryologists select these bound sperm for injection, as they are more likely to have better structural and DNA integrity.
Physiological intra-cytoplasmic sperm injection (PICSI) is not painful for patients. It is performed in the laboratory as part of IVF.
Procedures such as egg retrieval are carried out under sedation, ensuring comfort and minimal discomfort throughout treatment.
Physiological intra-cytoplasmic sperm injection (PICSI) can improve fertilisation quality in selected cases by enhancing sperm selection.
However, overall success depends on multiple factors such as egg quality, embryo development, and uterine conditions.
Physiological intra-cytoplasmic sperm injection (PICSI) is not required for all patients.
We only recommend it when clinical findings such as sperm quality, previous IVF outcomes, and reproductive history indicate a potential benefit.
At Sunfert, transparency is a core value. We only recommend additional procedures when there is clear clinical evidence that they may benefit our patients.
Yes. Physiological intra-cytoplasmic sperm injection (PICSI) is an additional laboratory technique.
It is only recommended when it is likely to improve treatment outcomes, particularly in specific cases where selecting higher-quality sperm can make a meaningful difference.
At Sunfert, we aim to ensure that any additional procedures are only advised when there is clear clinical benefit, so patients are not undergoing or paying for steps that are not necessary for their fertility journey and treatment.
Physiological intra-cytoplasmic sperm injection (PICSI) may be recommended after a detailed fertility assessment.
Our fertility specialist at Sunfert will evaluate sperm quality, medical history, and previous treatment outcomes to determine whether it could improve your IVF cycle.
Physiological intra-cytoplasmic sperm injection (PICSI) can be combined with Pre-implantation Genetic Testing (PGT-A or PGT-M) to screen embryos for chromosomal or genetic disorder before transfer, providing additional reproductive insight.
Egg freezing (oocyte cryopreservation) is a medical procedure where a woman’s eggs are collected, frozen, and stored for future use. It helps preserve fertility and allows women to attempt pregnancy at a later stage when they are ready.
Egg freezing is often chosen to preserve fertility before the natural decline in egg quantity and quality.
It provides reproductive flexibility for women who wish to delay childbirth due to career, education, or personal goals, or for those who planned to undergo medical treatment that may affecting their fertility.
Egg freezing may be suitable for women who are delaying parenthood, have medical conditions such as endometriosis, are planning cancer treatments like chemotherapy or radiotherapy, or wish to preserve fertility for future family planning.
The ideal time for egg freezing is before the age of 35, as egg quality and quantity decline with age.
However, it can still be considered at later ages depending on individual fertility assessment results and personal circumstances.
Egg freezing involves ovarian stimulation using hormonal medication to encourage the ovaries to produce multiple eggs.
This process usually starts at the beginning of the menstrual cycle and lasts around 10 to 12 days under medical supervision.
Egg freezing includes a procedure called oocyte pick-up (OPU), where eggs are collected from the ovaries using a minimally invasive technique.
It is performed under sedation and typically takes around 20 to 30 minutes with minimal discomfort.
After egg freezing, the collected eggs are preserved using a technique called vitrification.
This rapid freezing method protects egg quality and allows long-term storage in secure laboratory conditions.
Frozen eggs can be safely stored for many years. Current medical evidence shows that eggs remain viable for over 10 years when properly preserved using vitrification and maintained in controlled laboratory conditions.
However, under Malaysian regulations, fertility centres may store eggs, sperm, embryos, and ovarian tissue for up to 10 years.
Any request for storage beyond this period requires approval from the Ministry of Health Malaysia.
At Sunfert, we assist patients who wish to extend their storage by guiding them through the approval process.
Pregnancy success with frozen eggs depends mainly on the age at which the eggs were frozen and the number of eggs stored.
Younger eggs generally have higher success rates, and fertility specialists can provide personalised guidance based on individual assessment.
When ready, frozen eggs are thawed, fertilised through IVF, and developed into embryos.
The best-quality embryo is then transferred into the uterus to achieve pregnancy, with remaining embryos optionally frozen for future use.
Sperm freezing (sperm cryopreservation) is a process where sperm is collected, frozen at very low temperatures, and stored for future use.
It allows men to preserve fertility and use the sperm later in treatments such as IVF or IUI when they are ready to start a family.
Sperm freezing works by collecting a semen sample, analysing sperm quality, and then freezing healthy sperm in liquid nitrogen at –196°C.
This preserves the sperm so it can be thawed and used later for assisted reproductive treatments when needed.
Sperm freezing is suitable for men who are delaying fatherhood, undergoing medical treatments such as chemotherapy or radiotherapy, have conditions affecting fertility, or may not be available on the day of procedures like oocyte pick-up (OPU).
Sperm freezing is recommended before treatments or situations that may affect fertility, such as cancer therapy, major surgery involving the reproductive system, or when there is a risk of declining sperm quality over time.
Sperm freezing is not painful.
The process usually involves providing a semen sample in a private room or at home.
No surgical procedure is required, making it a simple and non-invasive fertility preservation method.
Semen is usually collected through masturbation in a private room at the fertility centre. In some cases, a collection kit can be provided for home collection to ensure comfort and convenience.
Before sperm freezing, a semen analysis is carried out to assess sperm count, movement (motility), and shape (morphology).
This helps identify the healthiest sperm for long-term storage.
Yes. Frozen sperm can be thawed and used in IVF or IUI treatments.
Many healthy pregnancies have been achieved using frozen sperm through assisted reproductive technology.
Sperm can be safely stored for many years in liquid nitrogen at –196°C.
Studies show that properly frozen sperm can remain viable for long-term use without significant loss of quality.
However, under Malaysian regulations, fertility centres are permitted to store eggs, sperm, embryos, and ovarian tissue for up to 10 years. Any storage beyond this period requires approval from the Ministry of Health Malaysia.
At Sunfert, we support patients who wish to extend their storage by guiding them through the approval process.
Embryo freezing, also known as embryo cryopreservation, is a laboratory process where embryos created through IVF are preserved for future use.
After fertilisation, embryos are developed in the lab and then frozen at –196°C using a method called vitrification.
This allows patients to use the embryos at a later stage when they are ready for pregnancy.
Vitrification is a rapid freezing technique used in advanced IVF laboratories.
It prevents ice crystal formation, which can damage embryo cells, by cooling embryos extremely quickly.
This method helps maintain embryo quality and results in high survival rates after thawing.
Embryo freezing is suitable for couples undergoing IVF with surplus good-quality embryos, patients undergoing medical treatments such as chemotherapy, individuals at risk of Ovarian Hyperstimulation Syndrome (OHSS), and those planning to delay pregnancy.
At Sunfert, our fertility specialist will recommend couples based on their fertility conditions and treatment plan.
Yes, embryo freezing is often an integral part of IVF.
After fertilisation, any suitable embryos can be frozen for future use instead of being transferred immediately.
This helps maximise the chances of pregnancy across multiple treatment cycles.
Embryos can remain safely frozen for many years without significant impact on their quality or potential for pregnancy.
Research and clinical evidence show that long-term storage does not reduce success rates when embryos are thawed and transferred.
With advanced vitrification techniques, embryo damage is extremely rare.
The process is designed to protect cellular structure, and most embryos survive the thawing process with their developmental potential intact.
Frozen embryo transfer (FET) is a procedure where previously frozen embryos are thawed and transferred into the uterus.
It allows pregnancy to be achieved in a later cycle without repeating ovarian stimulation or egg retrieval.
Yes, embryo freezing using vitrification is a safe and widely established technique used globally in IVF practice.
It is performed under strict laboratory conditions to ensure embryo protection and high success outcomes.
Embryo freezing can improve cumulative IVF success rates by allowing multiple transfer attempts from a single egg retrieval cycle.
This reduces the need for repeated ovarian stimulation and provides flexibility in planning pregnancy.
Embryo freezing allows fertility preservation, better cycle planning, and improved cumulative pregnancy chances.
It also supports patients who need medical treatment or wish to delay pregnancy while preserving high-quality embryos for future use.
In most IVF cycles involving Pre-implantation Genetic Testing (PGT), embryo freezing is mandatory.
This is because the genetic testing process takes time to analyse the embryos in the laboratory.
Once the results are ready, only chromosomally normal (euploid) embryos, or those free from genetic disorders, are selected and transferred in a later frozen embryo transfer (FET) cycle.
Ovarian tissue cryopreservation (OTC) is a fertility preservation technique where a small portion of ovarian tissue is surgically removed, frozen, and stored for future use.
The tissue contains immature eggs that may later support fertility when re-implanted or used in assisted reproduction such as IVF.
Advanced cryopreservation methods are used to maintain tissue viability at ultra-low temperatures, helping preserve reproductive potential for future pregnancy.
Ovarian tissue cryopreservation (OTC) is suitable for women at risk of losing fertility due to medical or genetic conditions.
This includes those undergoing chemotherapy or radiotherapy, individuals with conditions that may cause early ovarian failure, and women at risk of premature ovarian insufficiency.
A fertility assessment at a specialist centre such as Sunfert helps determine suitability.
The best time to consider Ovarian tissue cryopreservation (OTC) is before any treatment or condition that may affect ovarian function.
This includes prior to cancer treatment, fertility-impacting surgery, or when early ovarian decline is diagnosed.
Earlier preservation generally improves the chances of future reproductive success.
Yes, ovarian tissue cryopreservation (OTC) is a safe and is performed under strict clinical protocols by our experienced fertility specialists.
Ovarian tissue can be safely stored for many years without loss of viability.
Clinical studies have reported successful pregnancies even after long-term storage exceeding a decade, depending on individual circumstances and tissue quality.
However, under Malaysian regulations, fertility centres are allowed to store eggs, sperm, embryos, and ovarian tissue for up to 10 years. Storage beyond this duration requires approval from the Ministry of Health Malaysia.
At Sunfert, we assist patients who wish to extend their storage through the necessary approval process.
Most patients experience mild discomfort after the procedure, with a short recovery period. Serious complications are rare. Any potential risks, such as bleeding or infection, are carefully discussed during consultation, and patients are closely monitored by our clinical team.
Ovarian tissue cryopreservation (OTC) does not guarantee pregnancy, but it significantly improves the possibility of future conception.
Success depends on factors such as age at the time of tissue freezing, overall health, and tissue quality.
A personalised consultation helps set realistic expectations and guide the best fertility pathway.
Frozen ovarian tissue can later be re-implanted or used alongside IVF treatment to restore hormonal function or support egg development.
This provides an opportunity for natural or assisted conception in the future, depending on individual medical circumstances.
Female reproductive surgery refers to minimally invasive procedures such as hysteroscopy and laparoscopy that treat conditions affecting the uterus, fallopian tubes, ovaries, and pelvic structures.
These conditions may include fibroids, polyps, endometriosis, or adhesions.
By correcting structural abnormalities and improving reproductive health, the surgery can enhance natural conception chances and improve IVF success rates.
Reproductive surgery can help manage several fertility-related conditions, including uterine fibroids, endometrial polyps, uterine septum, endometriosis, pelvic adhesions, and blocked fallopian tubes.
Treating these conditions may improve fertility outcomes and reduce the risk of miscarriage in certain patients.
Hysteroscopy examines and treats conditions inside the uterus using a thin camera inserted through the vagina, with no external cuts.
Laparoscopy is a keyhole surgery performed through small abdominal incisions to examine and treat pelvic organs such as the uterus, ovaries, and fallopian tubes.
Both are minimally invasive and commonly used in fertility care.
Neither procedure is universally better, as each is used for different conditions.
Hysteroscopy is ideal for uterine issues such as polyps or fibroids, while laparoscopy is more suitable for endometriosis, adhesions, or blocked tubes.
A fertility specialist will recommend the most appropriate option based on diagnostic findings.
The procedure is usually performed under sedation or light anaesthesia, so patients do not feel pain during surgery.
After the procedure, mild cramping or discomfort similar to period pain may occur but typically resolves within a few days with simple medication.
Recovery depends on the type of procedure. Most patients recover from hysteroscopy within 1 to 3 days, while laparoscopy may require around 1 to 2 weeks for full recovery.
As both are minimally invasive, downtime is generally shorter compared to traditional surgery.
Yes, in many cases. If infertility is caused by conditions such as endometriosis, fibroids, adhesions, or blocked fallopian tubes, surgical treatment can improve reproductive function and increase the chances of natural conception.
It depends on your individual fertility condition, age, and medical history. Some patients may conceive naturally after surgery, while others may still require IVF for better success rates.
A fertility assessment helps determine the most suitable treatment pathway.
Minimally invasive techniques such as hysteroscopy and laparoscopy offer faster recovery, minimal scarring, reduced pain, and accurate diagnosis and treatment in a single procedure.
These benefits make them an important part of modern fertility management.
Reproductive surgery may be considered if you experience difficulty conceiving, recurrent miscarriage, irregular menstrual cycles, or symptoms suggestive of uterine or pelvic conditions.
At Sunfert, our fertility specialists can help determine whether surgery is appropriate for your situation.
Male reproductive surgery refers to minimally invasive or microsurgical sperm retrieval techniques used to help men with infertility, particularly when sperm is absent or difficult to access in the semen.
Procedures such as MESA, PESA, TESA, and TESE allow sperm to be retrieved directly from the epididymis or testicular tissue for use in assisted reproduction like IVF or ICSI.
Male reproductive surgery is typically recommended when a man has azoospermia (no sperm in ejaculate), a blockage in the reproductive tract or severely low sperm count.
A fertility assessment helps determine the most suitable approach.
Azoospermia is a condition where no sperm is present in the semen. It can be obstructive (caused by a blockage) or non-obstructive (caused by reduced sperm production).
Surgical sperm retrieval techniques such as PESA, TESA, TESE, or MESA may be used to retrieve sperm directly for fertility treatment.
Microsurgical Testicular Sperm Extraction (MESA): Uses microsurgery to retrieve sperm from the epididymis.
Percutaneous Testicular Sperm Aspiration (PESA): Uses a fine needle to aspirate sperm from the epididymis.
Testicular Sperm Aspiration (TESA): Retrieves sperm directly from the testicle using needle aspiration.
Testicular Sperm Extraction (TESE): Involves taking a small biopsy of testicular tissue to locate sperm.
Each technique is selected based on the underlying cause of infertility.
Microsurgical Testicular Sperm Extraction (MESA) is performed under anaesthesia to ensure minimal discomfort during the procedure.
Most patients experience mild soreness afterwards, and recovery is usually quick, with many returning to light activities within a few days.
Yes, Percutaneous Testicular Sperm Aspiration (PESA) is a safe and commonly used procedure for obstructive azoospermia.
It is minimally invasive, performed under local anaesthesia, and does not require open surgery.
Recovery is typically fast with minimal discomfort.
Yes, Testicular Sperm Aspiration (TESA) can be repeated if clinically appropriate.
The decision depends on medical evaluation, underlying fertility condition, and previous sperm retrieval outcomes.
Our fertility specialist will advise on timing and suitability for repeat procedures.
Testicular Sperm Extraction (TESE) is usually recommended when needle-based methods like TESA or PESA do not successfully retrieve sperm, or when a larger tissue sample is needed to improve the chances of finding viable sperm, especially in cases of non-obstructive azoospermia.
Most male reproductive procedures are performed under local or general anaesthesia to minimise pain.
Patients may experience mild swelling or discomfort afterwards, which usually resolves within a few days with standard post-procedure care.
Yes, sperm retrieved through MESA, PESA, TESA, or TESE can be used for IVF or ICSI treatment.
In many cases, ICSI (Intracytoplasmic Sperm Injection) is recommended to maximise fertilisation success using retrieved sperm.
The MindBody Fertility programme is a structured emotional wellbeing support initiative designed to help individuals and couples manage the psychological stress of fertility treatment.
It combines professional counselling, stress management techniques, and emotional support to complement medical care during IVF or other fertility treatments.
Fertility treatment can be emotionally challenging due to uncertainty, repeated cycles of hope, and treatment demands.
Stress and emotional strain may affect overall wellbeing and coping ability.
Emotional support helps patients manage anxiety, stay resilient, and maintain a balanced mindset throughout their fertility journey.
The programme provides confidential counselling sessions, stress management strategies, and emotional resilience training.
Each session is conducted privately with a certified counsellor to ensure personalised support, helping patients feel more supported and mentally prepared during treatment.
During a session, patients receive professional counselling in a safe and private environment.
The counsellor helps identify emotional challenges, teaches practical coping techniques such as relaxation and stress reduction, and supports patients in building emotional strength throughout their fertility journey.
Yes, it is often integrated as part of a holistic IVF care approach.
At Sunfert, the MindBody Fertility programme is included in most of our IVF packages to ensure that emotional wellbeing is supported alongside medical treatment, improving the overall patient experience.
In many fertility treatment packages, 4 complimentary MindBody Fertility counselling sessions are included as part of holistic care.
Patients are encouraged to check their specific package details, and additional sessions can also be arranged if further emotional support is needed, but additonal charges required.
Typically, 4 complimentary counselling sessions are included in most of our fertility treatment packages at Sunfert.
These sessions are designed to provide consistent emotional support before, during, and after treatment cycles.
Additional sessions may be arranged if required.
Yes, additional MindBody Fertility sessions can be arranged even after completing a treatment cycle.
Continued emotional support is available for patients who may need further guidance in coping with outcomes or planning next steps, but additonal charges required.
The sessions are conducted by certified counsellors with experience in fertility-related emotional care.
They provide professional, confidential, and empathetic support tailored to each patient’s individual needs and treatment journey.
Emotional wellbeing does not directly determine medical success, but high stress levels may affect coping ability and overall experience during treatment.
Supporting mental health helps patients remain engaged, resilient, and better prepared throughout their fertility journey.
Sperm and egg donation are assisted reproductive treatments where donor sperm or donor eggs are used to help achieve pregnancy when a couple’s own gametes cannot be used.
The treatment allows one parent to maintain a biological connection with the child while supporting conception through IVF.
At Sunfert, the process is medically supervised, ethically regulated, and strictly confidential.
Egg donation may be recommended when a woman has low ovarian reserve, poor egg quality, premature ovarian insufficiency, advanced maternal age, genetic conditions, or repeated IVF failure related to egg factors.
It provides an opportunity to achieve pregnancy when own eggs are unlikely to result in a successful outcome.
Sperm donation is considered when there is severe male factor infertility such as azoospermia, genetic disorders in the male partner, or when viable sperm cannot be retrieved through surgical methods.
Donor sperm offers a safe and effective option for achieving pregnancy through assisted reproduction.
Yes, in most donor conception cases, one partner still contributes genetically.
This allows the child to share a biological connection with at least one intended parent.
Donor selection is guided by medical and personal preferences.
Couples may consider physical traits (such as height, ethnicity, and appearance), medical and genetic screening results, blood type compatibility, educational background, and lifestyle factors.
All donor information is shared under strict confidentiality and ethical guidelines.
Yes, donor programmes are safe and properly regulated.
Donors undergo strict medical, infectious disease, and genetic screening before approval.
At Sunfert, we follow international standards to ensure safety, confidentiality, and quality control throughout the process.
Yes, it is completely normal to experience mixed emotions such as hope, grief, uncertainty, or relief.
Many couples go through a period of emotional adjustment when considering donor conception, especially regarding genetic connection and family identity.
Counselling support is an important part of the process.
Hence, at Sunfert, we provide counselling support for couples and the donors.
Counselling is a mandatory part of donor programmes to ensure emotional readiness and informed decision-making.
It helps couples understand long-term implications, manage emotional responses, discuss disclosure to future children, and align expectations. It also ensures donors fully understand their role and responsibilities.
The process includes medical screening, infectious disease and genetic testing, psychological counselling, specialist consultation, and donor selection.
For egg donation, monitored stimulation and egg retrieval are performed.
For sperm donation, semen samples are collected and screened.
All steps are carried out under strict clinical and ethical supervision.
Donor identity is managed under strict confidentiality protocols.
In most cases, donor details are non-identifiable, although certain medical and background information is shared for selection purposes.
The level of anonymity depends on programme regulations and clinical policies.
No fertility treatment can guarantee pregnancy.
However, using donor eggs or sperm may significantly improve success rates in suitable cases, particularly when infertility is related to egg or sperm quality.
Final outcomes still depend on multiple factors, including maternal age, uterine health, and overall clinical condition.
At Sunfert, we assure our patients that our fertility specialists’ expertise, clinical experience, and advanced laboratory technology meet world-class standards.
Donors undergo comprehensive medical screening, genetic testing, infectious disease testing, psychological assessment, and counselling.
Only individuals who meet strict health and ethical criteria are approved.
This ensures safety for recipients and future offspring.
Donors may receive compensation for their time, medical procedures, and commitment to the programme.
Egg donors are compensated for stimulation, monitoring, and retrieval procedures, while sperm donors may receive reimbursement after completing screening and approval stages.
Full financial terms are explained transparently before participation.
Yes, donor sperm or eggs are commonly used in IVF and ICSI treatments.
The selected donor gametes are fertilised in the laboratory, and resulting embryos are transferred into the uterus to achieve pregnancy under standard IVF protocols.
Donor conception is usually considered after other fertility treatments have been explored or when medical conditions prevent the use of a patient’s own eggs or sperm.
Consultation with our fertility specialists and certified fertility counsellors helps assess medical suitability, emotional readiness, and available treatment options to support informed decision-making.
Artificial Oocyte Activation (AOA) is a specialised IVF laboratory technique used after Intra-Cytoplasmic Sperm Injection (ICSI) to help trigger egg activation.
In some cases, even after sperm is injected into the egg, natural activation signals may not occur. AOA helps stimulate this process so the egg can begin dividing and developing into an embryo.
It is only recommended for selected patients after clinical assessment by fertility specialists and embryologists.
After ICSI, the injected eggs are exposed to a controlled laboratory solution (calcium ionophore) for a short period.
This mimics the natural calcium signals that normally activate the egg after fertilisation.
The eggs are then washed and placed back into fresh culture media for continued embryo development.
Artificial Oocyte Activation (AOA) can benefit patients who have experienced fertilisation challenges, such as previous fertilisation failure after ICSI, very low fertilisation rates, severe male factor infertility, suspected sperm-related activation issues, or rare egg activation disorders.
At Sunfert, it is only recommended when there is clear clinical indication that it may improve fertilisation outcomes.
Artificial Oocyte Activation (AOA) is considered when previous IVF or ICSI cycles show poor or failed fertilisation, despite apparently normal egg and sperm quality.
Before recommending AOA, the clinical team reviews previous cycle outcomes, laboratory fertilisation data, and the couple’s reproductive history to ensure the approach is medically justified.
No. Artificial Oocyte Activation (AOA) is not part of routine IVF treatment and is not required for all patients.
It is a specialised add-on technique used only in selected cases where fertilisation problems are suspected.
Artificial Oocyte Activation (AOA) is performed in a highly controlled laboratory setting immediately after ICSI.
The injected eggs are briefly cultured in a calcium ionophore solution, then rinsed and returned to standard culture conditions.
This process is carried out by our well-trained and experienced embryologists following strict safety protocols to ensure optimal embryo development conditions.
Yes. When performed by experienced embryologists in a regulated IVF laboratory, Artificial Oocyte Activation (AOA) is safe. It has been used in assisted reproduction for many years at Sunfert.
Safety is ensured through strict laboratory protocols, careful timing, and controlled exposure to activation agents as well.
Artificial Oocyte Activation (AOA) may improve fertilisation rates in selected patients who have experienced fertilisation failure or activation issues.
However, it does not guarantee pregnancy or fertilisation. Outcomes still depend on multiple factors such as egg quality, sperm quality, embryo development, and uterine health.
No. Artificial Oocyte Activation (AOA) is only offered when there is a clear medical indication.
At Sunfert, treatment recommendations are based on clinical evidence, previous IVF outcomes, and individual fertility assessments to ensure personalised and appropriate care.
This is also to ensure that any additional procedures are recommended only when there is clear clinical benefit, so patients do not undergo or incur costs for steps that are not necessary for their fertility journey and treatment.
